Nevolat, Zentiva’s Affordable Weight-Loss Drug, Hits Market in December
Zentiva is set to release Nevolat, a generic version of the weight-loss drug liraglutide, on December 10 or 11. This move aims to provide a more affordable obesity treatment option for patients. Nevolat, containing the active ingredient liraglutide, works by stimulating increased insulin secretion, slowing stomach emptying, and suppressing appetite. It is available in prefilled pens of 3x3 ml and 5x3 ml, with an introductory price of €79 and ongoing therapy costing €129 per month. The drug is approved for obese patients with a BMI of 30 or higher and overweight individuals with a BMI of 27 or above who have weight-related comorbidities. It provides structured therapeutic support and allows patients and doctors to assess tolerability earlier with its daily use. Dr. Thomas Kurscheid, a general practitioner, supports the availability of affordable obesity treatment options. He believes Nevolat will benefit self-paying patients the most due to its significantly lower cost compared to the original brand-name drug. The exact prices for the pens will be known at launch, but estimates suggest 3×3 ml pens at approx. €222.20 and 5×3 ml pens at approx. €362.80. Zentiva aims to prevent supply bottlenecks experienced with similar drugs in the past, ensuring a smooth release from mid-December. Nevolat's launch on December 10 or 11 will provide a more affordable obesity treatment option, benefiting self-paying patients. With structured therapeutic support and lower costs, Nevolat aims to improve accessibility to weight-loss medication. Zentiva is committed to preventing supply issues, ensuring a smooth rollout from mid-December.
